News | March 27, 2026
CuraTeQ Biologics enters into agreement with STADA Arzneimittel AG
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
It promises fewer injections for vision loss patients
India’s largest glycolic acid manufacturer will unveil AviGa Bio HP70 on April 14, 2026
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations
Subscribe To Our Newsletter & Stay Updated
